Oncolytic herpes simplex virus vectors and chemotherapy: Are combinatorial strategies more effective for cancer?

Future Oncology

Volumn 6, Issue 4, 2010, Pages 619-634

  Kanai, Ryuichi ^a   Wakimoto, Hiroaki ^a   Cheema, Tooba ^a   Rabkin, Samuel D ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Chemotherapeutics; Combination therapy; Herpes simplex virus; Oncolytic virus; Prodrug activation; Virotherapy; Virotherapy cancer drug

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; CISPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; ERLOTINIB; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; G 207; GEMCITABINE; H 101; HSV 1716; IRINOTECAN; METHOTREXATE; MITOMYCIN C; NV 1020; ONCOLYTIC ADENOVIRUS; ONCOLYTIC HERPES VIRUS; ONCOLYTIC VIRUS MGH2; ONCOLYTIC VIRUS ONCDSYN; ONCOLYTIC VIRUS RQNESTIN34.5; ONYX 015; PACLITAXEL; TEMOZOLOMIDE; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VINCRISTINE; VIRUS VECTOR;

CANCER COMBINATION CHEMOTHERAPY; COLON CANCER; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; HEAD AND NECK CANCER; HERPES SIMPLEX VIRUS; HUMAN; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIPLE MYELOMA; NASOPHARYNX CANCER; NEOPLASM; ONCOLYTIC VIROTHERAPY; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; THERAPY EFFECT; VIRAL GENE DELIVERY SYSTEM; VIROTHERAPY; VIRUS REPLICATION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; GENE THERAPY; GENETIC VECTORS; HUMANS; NEOPLASMS; SIMPLEXVIRUS;

EID: 77950619654     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.18     Document Type: Review

References (114)

1. Guo ZS, Thorne SH, Bartlett DL: Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim. Biophys. Acta 1785, 217-231 (2008).
2. Kelly E, Russell SJ: History of oncolytic viruses: genesis to genetic engineering. Mol. Ther. 15, 651-659 (2007).
3. Russell SJ, Peng KW: Viruses as anticancer drugs. Trends Pharmacol. Sci. 28, 326-333 (2007).
4. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM: Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252, 854-856 (1991).
5. Kirn D: Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther. 8, 89-98 (2001).
6. Liu TC, Galanis E, Kirn D: Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat. Clin. Pract. Oncol. 4, 101-117 (2007).
7. Roizman B, Knipe DM, Whitley RJ. Herpes simplex viruses. In: Fields Virology (5th Edition). Knipe DM, Howley PM (Eds). Wolters Kluwer Health/ Lippincott Williams & Wilkins, PA, USA, 2501-2601 (2007).
8. Varghese S, Rabkin SD: Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther. 9, 967-978 (2002).
9. Shen Y, Nemunaitis J: Herpes simplex virus 1 (HSV-1) for cancer treatment. Cancer Gene Ther. 13, 975-992 (2006).
10. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL: Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med. 1, 938-943 (1995).
11. Aghi M, Rabkin S: Viral vectors as therapeutic agents for glioblastoma. Curr. Opin. Mol. Ther. 7, 419-430 (2005).
12. Reinblatt M, Pin RH, Fong Y: Herpes viral oncolysis: a novel cancer therapy. J. Am. Coll. Surg. 205, S69-S75 (2007).
13. Markert JM, Liechty PG, Wang W et al.: Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol. Ther. 17, 199-207 (2009).
14. Yun CO: Overcoming the extracellular matrix barrier to improve intratumoral spread and therapeutic potential of oncolytic virotherapy. Curr. Opin. Mol. Ther. 10, 356-361 (2008).
15. Wakimoto H, Johnson PR, Knipe DM, Chiocca EA: Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Ther. 10, 983-990 (2003).
16. Fukuhara H, Todo T: Oncolytic herpes simplex virus type 1 and host immune responses. Curr. Cancer Drug Targets 7, 149-155 (2007).
17. Senzer NN, Kaufman HL, Amatruda T et al.: Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J. Clin. Oncol. 27, 5763-5771 (2009).
18. Kumar S, Gao L, Yeagy B, Reid T: Virus combinations and chemotherapy for the treatment of human cancers. Curr. Opin. Mol. Ther. 10, 371-379 (2008).
19. Nguyen TL, Tumilasci VF, Singhroy D, Arguello M, Hiscott J: The emergence of combinatorial strategies in the development of RNA oncolytic virus therapies. Cell. Microbiol. 11, 889-897 (2009).
20. Alvarez-Breckenridge C, Kaur B, Chiocca EA: Pharmacologic and chemical adjuvants in tumor virotherapy. Chem. Rev. 109, 3125-3140 (2009).
21. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH: ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 3, 639-645 (1997).
22. Khuri FR, Nemunaitis J, Ganly I et al.: A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6, 879-885 (2000).
23. Reid T, Galanis E, Abbruzzese J et al.: Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a Phase I trial. Gene Ther. 8, 1618-1626 (2001).
24. Galanis E, Okuno SH, Nascimento AG et al.: Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther. 12, 437-445 (2005).
25. Nemunaitis J, Cunningham C, Tong AW et al.: Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. Cancer Gene Ther. 10, 341-352 (2003).
26. Hecht JR, Bedford R, Abbruzzese JL et al.: A Phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin. Cancer Res. 9, 555-561 (2003).
27. Yu W, Fang H: Clinical trials with oncolytic adenovirus in China. Curr. Cancer Drug Targets 7, 141-148 (2007).
28. Quirin C, Mainka A, Hesse A, Nettelbeck DM: Combining adenoviral oncolysis with temozolomide improves cell killing of melanoma cells. Int. J. Cancer 121, 2801-2807 (2007).
29. Leitner S, Sweeney K, Oberg D et al.: Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo. Clin. Cancer Res. 15, 1730-1740 (2009).
30. Nelson AR, Davydova J, Curiel DT, Yamamoto M: Combination of conditionally replicative adenovirus and standard chemotherapies shows synergistic antitumor effect in pancreatic cancer. Cancer Sci. 100, 2181-2187 (2009).
31. Sei S, Mussio JK, Yang QE et al.: Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells. Mol. Cancer 8, 47 (2009).
32. Coukos G, Makrigiannakis A, Kang EH, Rubin SC, Albelda SM, Molnar-Kimber KL: Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer. Clin. Cancer Res. 6, 3342-3353 (2000).
33. Chahlavi A, Todo T, Martuza RL, Rabkin SD: Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia 1, 162-169 (1999).
34. Gutermann A, Mayer E, Von Dehn-Rothfelser K et al.: Efficacy of oncolytic herpesvirus NV1020 can be enhanced by combination with chemotherapeutics in colon carcinoma cells. Hum. Gene Ther. 17, 1241-1253 (2006).
35. Aghi M, Rabkin S, Martuza RL: Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J. Natl Cancer Inst. 98, 38-50 (2006).
36. Fukuhara H, Martuza RL, Rabkin SD, Ito Y, Todo T: Oncolytic herpes simplex virus vector G47D in combination with androgen ablation for the treatment of human prostate adenocarcinoma. Clin. Cancer Res. 11, 7886-7890 (2005).
37. Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22, 27-55 (1984).
38. Chou TC: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621-681 (2006).
39. Chou TC: Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70, 440-446 (2010).
40. Reynolds CP, Maurer BJ: Evaluating response to antineoplastic drug combinations in tissue culture models. Methods Mol. Med. 110, 173-183 (2005).
41. Watanabe I, Kasuya H, Nomura N et al.: Effects of tumor selective replication-competent herpes viruses in combination with gemcitabine on pancreatic cancer. Cancer Chemother. Pharmacol. 61, 875-882 (2008).
42. Nguyen ML, Blaho JA: Apoptosis during herpes simplex virus infection. Adv. Virus Res. 69, 67-97 (2007).
43. Hibma MH, Real NC, Wiles A et al.: Increased apoptosis and reduced replication efficiency of the E3 region-modified dl309 adenovirus in cancer cells. Virus Res. 145, 112-120 (2009).
44. Kasuya H, Nishiyama Y, Nomoto S et al.: Suitability of a US3-inactivated HSV mutant (L1BR1) as an oncolytic virus for pancreatic cancer therapy. Cancer Gene Ther. 14, 533-542 (2007).
45. Aghi M, Rabkin SD, Martuza RL: Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide. Cancer Res. 67, 440-444 (2007).
46. Kurozumi K, Hardcastle J, Thakur R et al.: Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J. Natl Cancer Inst. 99, 1768-1781 (2007).
47. Kaur B, Cripe TP, Chiocca EA: "Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment. Curr. Gene Ther. 9, 341-355 (2009).
48. Toyoizumi T, Mick R, Abbas AE, Kang EH, Kaiser LR, Molnar-Kimber KL: Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer. Hum. Gene Ther. 10, 3013-3029 (1999).
49. Mohr I: To replicate or not to replicate: achieving selective oncolytic virus replication in cancer cells through translational control. Oncogene 24, 7697-7709 (2005).
50. Petrowsky H, Roberts GD, Kooby DA et al.: Functional interaction between fluorodeoxyuridine-induced cellular alterations and replication of a ribonucleotide reductase-negative herpes simplex virus. J. Virol. 75, 7050-7058 (2001).
51. Nakano K, Todo T, Zhao G et al.: Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models. J. Gene Med. 7, 638-648 (2005).
52. Eisenberg DP, Adusumilli PS, Hendershott KJ et al.: 5-fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer. J. Gastrointest. Surg. 9, 1068-1077 (2005).
53. Bennett JJ, Adusumilli P, Petrowsky H et al.: Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a g134.5 deleted oncolytic herpes virus (G207). FASEB J. 18, 1001-1003 (2004). (Pubitemid 39561505)
54. Mullerad M, Bochner BH, Adusumilli PS et al.: Herpes simplex virus based gene therapy enhances the efficacy of mitomycin C for the treatment of human bladder transitional cell carcinoma. J. Urol. 174, 741-746 (2005). (Pubitemid 40981647)
55. Hadjipanayis CG, Fellows-Mayle W, Deluca NA: Therapeutic efficacy of a herpes simplex virus with radiation or temozolomide for intracranial glioblastoma after convection-enhanced delivery. Mol. Ther. 16, 1783-1788 (2008).
56. Stahel RA, Felley-Bosco E, Opitz I, Weder W: Malignant pleural mesothelioma. Future Oncol. 5(3), 391-402 (2009).
57. Adusumilli PS, Chan MK, Chun YS et al.: Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma. Cancer Biol. Ther. 5, 48-53 (2006).
58. Lin SF, Gao SP, Price DL et al.: Synergy of a herpes oncolytic virus and paclitaxel for anaplastic thyroid cancer. Clin. Cancer Res. 14, 1519-1528 (2008). (Pubitemid 351413937)
59. Passer BJ, Castelo-Branco P, Buhrman JS, Varghese S, Rabkin SD, Martuza RL: Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells. Cancer Gene Ther. 16, 551-560 (2009).
60. Shimoyama S, Goshima F, Teshigahara O et al.: Enhanced efficacy of herpes simplex virus mutant HF10 combined with paclitaxel in peritoneal cancer dissemination models. Hepatogastroenterology 54, 1038-1042 (2007). (Pubitemid 47013900)
61. Cinatl J Jr, Cinatl J, Michaelis M et al.: Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma. Cancer Res. 63, 1508-1514 (2003). (Pubitemid 36373636)
62. Toda M, Rabkin SD, Kojima H, Martuza RL: Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum. Gene Ther. 10, 385-393 (1999). (Pubitemid 29097317)
63. Lee KC, Hamstra DA, Bhojani MS, Khan AP, Ross BD, Rehemtulla A: Noninvasive molecular imaging sheds light on the synergy between 5-fluorouracil and TRAIL/Apo2L for cancer therapy. Clin. Cancer Res. 13, 1839-1846 (2007). (Pubitemid 46952954)
64. Nakamura M, Nagano H, Sakon M et al.: Role of the Fas/FasL pathway in combination therapy with interferon-a and fluorouracil against hepatocellular carcinoma in vitro. J. Hepatol. 46, 77-88 (2007). (Pubitemid 44827417)
65. Qiu S, Ruan H, Pei Z et al.: Combination of targeting gene-virotherapy with 5-FU enhances antitumor efficacy in malignant colorectal carcinoma. J. Interferon Cytokine Res. 24, 219-230 (2004). (Pubitemid 38526782)
66. Mace AT, Harrow SJ, Ganly I, Brown SM: Cytotoxic effects of the oncolytic herpes simplex virus HSV1716 alone and in combination with cisplatin in head and neck squamous cell carcinoma. Acta Otolaryngol. 127, 880-887 (2007). (Pubitemid 47344054)
67. Carew JS, Giles FJ, Nawrocki ST: Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 269, 7-17 (2008).
68. Marks PA, Xu WS: Histone deacetylase inhibitors: potential in cancer therapy. J. Cell. Biochem. 107, 600-608 (2009).
69. Otsuki A, Patel A, Kasai K et al.: Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol. Ther. 16, 1546-1555 (2008).
70. Nguyen TL, Abdelbary H, Arguello M et al.: Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc. Natl Acad. Sci. USA 105, 14981-14986 (2008).
71. Hoti N, Chowdhury W, Hsieh JT, Sachs MD, Lupold SE, Rodriguez R: Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy. Mol. Ther. 14, 768-778 (2006). (Pubitemid 44780612)
72. Liu TC, Castelo-Branco P, Rabkin SD, Martuza RL: Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and anti-angiogenic effects. Mol. Ther. 16, 1041-1047 (2008). (Pubitemid 351737068)
73. Katsura T, Iwai S, Ota Y, Shimizu H, Ikuta K, Yura Y: The effects of trichostatin A on the oncolytic ability of herpes simplex virus for oral squamous cell carcinoma cells. Cancer Gene Ther. 16, 237-245 (2009).
74. Liu P, Cheng H, Roberts TM, Zhao JJ: Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 8, 627-644 (2009).
75. Benetti L, Roizman B: Protein kinase B/Akt is present in activated form throughout the entire replicative cycle of DU(S)3 mutant virus but only at early times after infection with wild-type herpes simplex virus 1. J. Virol. 80, 3341-3348 (2006).
76. Liu TC, Wakimoto H, Martuza RL, Rabkin SD: Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeutics. Clin. Cancer Res. 13, 5897-5902 (2007). (Pubitemid 47583917)
77. Sarinella F, Calistri A, Sette P, Palu G, Parolin C: Oncolysis of pancreatic tumour cells by a g34.5-deleted HSV-1 does not rely upon Ras-activation, but on the PI 3-kinase pathway. Gene Ther. 13, 1080-1087 (2006).
78. Mahller YY, Vaikunth SS, Currier MA et al.: Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model. Mol. Ther. 15, 279-286 (2007).
79. Palumbo A, Facon T, Sonneveld P et al.: Thalidomide for treatment of multiple myeloma: 10 years later. Blood 111, 3968-3977 (2008).
80. Israyelyan A, Shannon EJ, Baghian A, Kearney MT, Kousoulas KG: Thalidomide suppressed the growth of 4T1 cells into solid tumors in Balb/c mice in a combination therapy with the oncolytic fusogenic HSV-1 OncdSyn. Cancer Chemother. Pharmacol. 64, 1201-1210 (2009).
81. Portsmouth D, Hlavaty J, Renner M: Suicide genes for cancer therapy. Mol. Aspects Med. 28, 4-41 (2007).
82. Chase M, Chung RY, Chiocca EA: An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat. Biotechnol. 16, 444-448 (1998).
83. Braidwood L, Dunn PD, Hardy S, Evans TR, Brown SM: Antitumor activity of a selectively replication competent herpes simplex virus (HSV) with enzyme prodrug therapy. Anticancer Res. 29, 2159-2166 (2009).
84. Todo T, Rabkin SD, Martuza RL: Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors. Cancer Gene Ther. 7, 939-946 (2000).
85. Luo C, Mori I, Goshima F et al.: Replication-competent, oncolytic herpes simplex virus type 1 mutants induce a bystander effect following ganciclovir treatment. J. Gene Med. 9, 875-883 (2007).
86. Guffey MB, Parker JN, Luckett WS Jr et al.: Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors. Cancer Gene Ther. 14, 45-56 (2007).
87. Tyminski E, Leroy S, Terada K et al.: Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan. Cancer Res. 65, 6850-6857 (2005).
88. Ishida D, Nawa A, Tanino T et al.: Enhanced cytotoxicity with a novel system combining the paclitaxel-2́-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus. Cancer Lett. 288(1), 17-27 (2009).
89. Fulci G, Breymann L, Gianni D et al.: Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc. Natl Acad. Sci. USA 103, 12873-12878 (2006). (Pubitemid 44298654)
90. Li H, Zeng Z, Fu X, Zhang X: Coadministration of a herpes simplex virus-2 based oncolytic virus and cyclophosphamide produces a synergistic antitumor effect and enhances tumor-specific immune responses. Cancer Res. 67, 7850-7855 (2007).
91. Pawlik TM, Nakamura H, Mullen JT et al.: Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene. Cancer 95, 1171-1181 (2002).
92. Currier MA, Gillespie RA, Sawtell NM et al.: Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide. Mol. Ther. 16, 879-885 (2008).
93. Orvedahl A, Alexander D, Talloczy Z et al.: HSV-1 ICP34.5 confers neurovirulence by targeting the Beclin 1 autophagy protein. Cell Host Microbe 1, 23-35 (2007).
94. Fong Y, Kim T, Bhargava A et al.: A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer. Mol. Ther. 17, 389-394 (2009).
95. Huang C, Li M, Chen C, Yao Q: Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications. Expert Opin. Ther. Targets 12, 637-645 (2008).
96. Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 10, 704-714 (2009).
97. Diehn M, Cho RW, Clarke MF: Therapeutic implications of the cancer stem cell hypothesis. Semin. Radiat. Oncol. 19, 78-86 (2009).
98. Wakimoto H, Kesari S, Farrell CJ et al.: Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res. 69, 3472-3481 (2009).
99. Mahller YY, Williams JP, Baird WH et al.: Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS One 4, E4235 (2009).
100. Friedman GK, Langford CP, Coleman JM et al.: Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111. J. Neurooncol. 95, 199-209 (2009).
101. Tesniere A, Panaretakis T, Kepp O et al.: Molecular characteristics of immunogenic cancer cell death. Cell Death Differ. 15, 3-12 (2008).
102. MacLean AR, ul-Fareed M, Robertson L, Harland J, Brown SM: Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence. J. Gen. Virol. 72, 631-639 (1991).
103. Liu BL, Robinson M, Han ZQ et al.: ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 10, 292-303 (2003).
104. Wong RJ, Kim SH, Joe JK, Shah JP, Johnson PA, Fong Y: Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus. J. Am. Coll. Surg. 193, 12-21 (2001).
105. Takakuwa H, Goshima F, Nozawa N et al.: Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice. Arch. Virol. 148, 813-825 (2003).
106. Todo T, Martuza RL, Rabkin SD, Johnson PA: Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc. Natl Acad. Sci. USA 98, 6396-6401 (2001).
107. Chou J, Kern ER, Whitley RJ, Roizman B: Mapping of herpes simplex virus-1 neurovirulence to g34.5, a gene nonessential for growth in culture. Science 250, 1262-1266 (1990).
108. Goldstein DJ, Weller SK: Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensible for virus growth and DNA synthesis: isolation and characterization of an ICP6 LacZ insertion mutant. J. Virol. 62, 196-205 (1988).
109. Kambara H, Okano H, Chiocca EA, Saeki Y: An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res. 65, 2832-2839 (2005).
110. Wong RJ, Joe JK, Kim SH, Shah JP, Horsburgh B, Fong Y: Oncolytic herpesvirus effectively treats murine squamous cell carcinoma and spreads by natural lymphatics to treat sites of lymphatic metastases. Hum. Gene Ther. 13, 1213-1223 (2002).
111. Purves FC, Longnecker RM, Leader DP, Roizman B: Herpes simplex virus 1 protein kinase is encoded by open reading frame US3 which is not essential for virus growth in cell culture. J. Virol. 61, 2896-2901 (1987).
112. Andreansky S, Soroceanu L, Flotte ER et al.: Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res. 57, 1502-1509 (1997). (Pubitemid 27175567)
113. Israyelyan A, Chouljenko VN, Baghian A, David AT, Kearney MT, Kousoulas KG: Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice. Virol. J. 5, 68 (2008). (Pubitemid 351962614)
114. Nagano S, Perentes JY, Jain RK, Boucher Y: Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors. Cancer Res. 68, 3795-3802 (2008).